The Effect of Pre-admission Hydroxychloroquine Treatment on COVID-19-Related Intensive Care Follow-up in Geriatric Patients
Çiyiltepe et al.
, The Effect of Pre-admission Hydroxychloroquine Treatment on COVID-19-Related Intensive Care Follow-up in..
, South. Clin. Ist. Euras., doi:10.14744/scie.2021.89847
Retrospective 147 ICU patients in Turkey, showing no significant difference in outcomes based on HCQ treatment before ICU admission. This is not very informative, for example we do not know if HCQ treated patients were much less likely to be admitted to the ICU.
This study is excluded in the after exclusion results of meta
treatment group only includes patients where treatment failed resulting in ICU admission.
risk of death, 3.2% lower, RR 0.97, p = 0.85, treatment 69 of 95 (72.6%), control 39 of 52 (75.0%), NNT 42.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Çiyiltepe et al., 30 Apr 2021, retrospective, Turkey, peer-reviewed, 5 authors.
Abstract: DOI: 10.14744/scie.2021.89847
South. Clin. Ist. Euras. 2021;32(3):235-240
The Effect of Pre-admission
Hydroxychloroquine Treatment on
COVID-19-Related Intensive Care
Follow-up in Geriatric Patients
Fulya Çiyiltepe,1 Ayten Saracoglu,2
Elif Bombacı,1 Kemal Saracoglu1
Department of Anesthesiology and
Reanimation, University of Health
Sciences, İstanbul Kartal Dr. Lütfi
Kırdar City Hospital, İstanbul, Turkey
Department of Anesthesiology and
Reanimation, Marmara University
Faculty of Medicine, İstanbul, Turkey
Correspondence: Fulya Çiyiltepe,
SBÜ, İstanbul Kartal Dr. Lütfi Kırdar
Şehir Hastanesi, Anesteziyoloji ve
intensive care units; mortality.
This work is licensed under a Creative Commons
Attribution-NonCommercial 4.0 International License.
Objective: The admission rates to intensive care units and mortalities in geriatric patients
are higher than the rest of the population with COVID-19 infection. Although the efficacy
of hydroxychloroquine sulfate has been recognized, especially when started early during
infection, its effectiveness at these early time points in geriatric patients has not been investigated. In this study, our primary aim was to investigate the effects of early treatment
of hydroxychloroquine sulfate on COVID-19 positive geriatric patients, according to their
clinical symptoms, situation before the intensive care, and patient survival.
Methods: A total of 147 geriatric patients diagnosed with COVID-19 in the intensive care
unit were divided into three groups: Patients who were admitted to the intensive care unit
from the emergency department but did not receive treatment (Group 1); from the service
for whose a 5-day treatment was initiated but not completed (Group 2); and those who
completed 5-days of drug therapy (Group 3).
Results: Although demographic data were similar between the three groups, the age parameters were significantly differed between them. Furthermore, there was no difference
between the groups regarding mortality rate, discharge time, or extubation. The time to
mortality and the duration of mechanical ventilation were found to be significantly shorter
in Group 1 (p=0.001).
Conclusion: No significant effect was observed on patient survival and outcome due to
early administration of hydroxychloroquine sulfate.According to our main findings, this study
cannot recommend pre-admission hydroxychloroquine treatment for critically ill geriatric
patients with COVID-19.
is less effective
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation. FLCCC
provide treatment protocols.